Agreement - January 3, 2022
AstraZeneca and Ionis close agreement
AstraZeneca has closed a global development and commercialization agreement with Ionis Pharmaceuticals for eplontersen, formerly known as IONIS-TTR-LRX. The companies will jointly develop and commercialize eplontersen in the US, while AstraZeneca will develop and commercialize it in the rest of the world, except in Latin America. Financial considerations Under the terms of the agreement, the […]